Opinion|Videos|February 5, 2024
Bispecific Therapies: Current and Future Considerations
With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.
Advertisement
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Advertisement
Related to this article
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
3
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
4
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
5